BCDA — BioCardia, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 925741 ·
Last close
$1.06
Market Cap
$16.05M
52W High
$1.80
52W Low
$0.75
ADV30
287,843
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 0 | — | -2,266,000 | -2,259,000 | 1,712,000 | 951,000 | 2,778,000 |
| Dec 2025 | 0 | — | -2,013,000 | -1,984,000 | 3,413,000 | 2,496,000 | 2,518,000 |
| Sep 2025 | 0 | — | -1,488,000 | -1,483,000 | 6,148,000 | 5,287,000 | 3,521,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-7,477,000
Investing CF
$-10,000
Financing CF
$7,489,000
CapEx
$-10,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.44
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-170,608,000
Inventory
—
Receivables
$20,000
ST Investments
—
EBIT TTM
$-7,818,000
Pretax Income TTM
$-7,775,000
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -8,278,000 | -8,228,000 | 3,413,000 | 2,518,000 | 895,000 | -7,436,000 |
| Dec 2024 | 58,000 | -8,001,000 | -7,946,000 | 3,724,000 | 2,887,000 | 837,000 | -7,886,000 |
| Dec 2023 | 477,000 | -11,644,000 | -11,571,000 | 2,987,000 | 4,590,000 | -1,603,000 | -9,974,000 |
| Dec 2022 | 1,352,000 | -11,901,000 | -11,907,000 | 9,793,000 | 4,901,000 | 4,892,000 | -10,561,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$2,382,000
NetIncome TTM
$-7,775,000
OpCashFlow TTM
—
Assets (Latest)
$1,712,000
Forward EPS
$-0.58
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TCRX | TScan Therapeutics, Inc. | $14.49M | $0.23 | — |
| DYAI | DYADIC INTERNATIONAL INC | $17.80M | $0.44 | — |
| ESLA | Estrella Immunopharma, Inc. | $18.16M | $0.42 | — |
| JSPR | Jasper Therapeutics, Inc. | $18.63M | $0.56 | — |
| GRML | Greenland Mines Ltd | $18.68M | $5.88 | — |
News headlines (Yahoo Finance, 1h cache)
BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting
2026-10-07 13:00 · Yahoo
BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter
2026-10-01 13:15 · Yahoo
BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission
2026-09-23 13:15 · Yahoo
BioCardia to Present CardiAMP Regulatory and Corporate Progress at H.C. Wainwright 28th Annual Global Investment Conference
2026-09-10 12:30 · Yahoo
BioCardia Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting Minutes Supporting Follow-On De Novo Pre-Submission for Approval
2026-08-24 12:30 · Yahoo
BioCardia (BCDA) Q2 2026 Earnings Call Transcript
2026-08-19 22:28 · Yahoo
BioCardia Inc (BCDA) (Q2 2026) Earnings Call Highlights: Regulatory Wins in Japan and US ...
2026-08-13 05:04 · Yahoo
BioCardia Reports Second Quarter 2026 Business Highlights and Financial Results
2026-08-12 20:05 · Yahoo
BioCardia to Host Q2 2026 Financial Results and Corporate Update Conference Call on August 12, 2026
2026-08-05 19:16 · Yahoo
BioCardia, Inc. Q2 2026 Earnings Call Summary
2026-08-13 01:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.